Glucagon (19-29), human
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Glucagon是由胰腺分泌的一种肽类激素,氨基酸序列为NH2-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-COOH,可增加体内血糖水平。胰高血糖素的作用与胰岛素相反,胰岛素可以降低血糖含量。促分泌素可诱导胰岛素释放,Miniglucagon(胰高血糖素19-29)通过钙离子途径高效的抑制这个过程。Miniglucagon是胰岛生理学的一种新型的局部调节剂。在2型糖尿病中观察到,这种肽在β细胞中诱导的异常抑制可导致胰岛素分泌受损。Miniglucagon是胰高血糖素正性肌力作用的一种成分。证据表明,胰高血糖素在心脏收缩过程中发挥正性肌力作用,胰高血糖素转变成miniglucagon的过程对于正向肌力作用的产生是必不可少的。
参考文献:
1. Reece J, Campbell N (2002). Biology. San Francisco: Benjamin Cummings. ISBN 0-8053-6624-5.
2. Stéphane Dalle, Ghislaine Fontés, Anne-Dominique Lajoix2, Laurence LeBrigand, René Gross, Gérard Ribes, Michel Dufour, Léo Barry, Dung LeNguyen and Dominique Bataille, Miniglucagon (Glucagon 19-29) A Novel Regulator of the Pancreatic Islet Physiology, doi:10.2337/diabetes.51.2.406Diabetes February 2002 vol. 51 no. 2406-412
3. Pavoine C, Brechler V, Kervan A, Blache Kervan, Le-Nguyen D, Laurent S, Bataille D, Pecker F (1991) Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol 260:C993–C999.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 1352.51 |
Cas No. | 64790-15-4 |
Formula | C61H89N15O18S |
Synonyms | H2N-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH |
Solubility | insoluble in EtOH; insoluble in H2O; ≥135.2 mg/mL in DMSO |
Chemical Name | Glucagon (19-29), human |
SDF | Download SDF |
Canonical SMILES | CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)N |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Cell experiment:[1] | |
Cell lines |
MIN6 cells |
Reaction Conditions |
0.01 ~ 1000 pM miniglucagon for 2 h incubation |
Applications |
Miniglucagon dose-dependently (ID50 = 1 pM) inhibited by 80 ~ 100% the insulin release triggered by glucose, glucagon, glucagon-like peptide-1-(7-36) amide (tGLP-1), or glibenclamide. Miniglucagon, at the doses active on insulin release, was able to block the increase in 45Ca2+ uptake induced by depolarizing agents (glucose or extracellular K+), glucagon, or the Ca2+ channel agonist Bay K-8644. In addition, pretreatment with pertussis toxin abolished the effects of miniglucagon on insulin release. These data suggest that miniglucagon is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein. |
Note |
The technical data provided above is for reference only. |
References: 1. Dalle S, Smith P, Blache P, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. Journal of Biological Chemistry, 1999, 274(16): 10869-10876. |
质量控制和MSDS
- 批次: